Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Working Capital Changes: 2018-2024

Historic Other Working Capital Changes for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to $7.7 million.

  • Phathom Pharmaceuticals' Other Working Capital Changes fell 168.21% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 185.87%. This contributed to the annual value of $7.7 million for FY2024, which is 4.90% down from last year.
  • Phathom Pharmaceuticals' Other Working Capital Changes amounted to $7.7 million in FY2024, which was down 4.90% from $8.1 million recorded in FY2023.
  • Phathom Pharmaceuticals' 5-year Other Working Capital Changes high stood at $8.1 million for FY2023, and its period low was -$8.0 million during FY2020.
  • For the 3-year period, Phathom Pharmaceuticals' Other Working Capital Changes averaged around $5.9 million, with its median value being $7.7 million (2024).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first plummeted by 167.41% in 2020, then surged by 407.44% in 2022.
  • Over the past 5 years, Phathom Pharmaceuticals' Other Working Capital Changes (Yearly) stood at -$8.0 million in 2020, then soared by 92.40% to -$605,000 in 2021, then skyrocketed by 407.44% to $1.9 million in 2022, then skyrocketed by 333.71% to $8.1 million in 2023, then dropped by 4.90% to $7.7 million in 2024.